ORGANOGENESIS HOLDINGS INC. - CLASS A

Organogenesis Achieves Primary Endpoint in Phase 3 Clinical Trial of ReNu® for Knee Osteoarthritis

02 May 2024 06:00:01 By Nasdaq GlobeNewswire

Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2024 Financial Results on May 9, 2024

16 Apr 2024 06:30:00 By Nasdaq GlobeNewswire

Organogenesis Announces Favorable Court Ruling Dismissing Securities Fraud Case

03 Apr 2024 06:30:00 By Nasdaq GlobeNewswire

Organogenesis Holdings Inc. Reports Fourth Quarter 2023 and Fiscal Year 2023 Financial Results; Introduces Fiscal Year 2024 Guidance

29 Feb 2024 15:05:00 By Nasdaq GlobeNewswire

Organogenesis Holdings Inc. to Participate in the BTIG Snowbird MedTech, Digital Health, Life Science and Diagnostic Tools Conference

12 Feb 2024 06:30:00 By Nasdaq GlobeNewswire

Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2023 Financial Results on February 29, 2024

08 Feb 2024 15:05:00 By Nasdaq GlobeNewswire

Organogenesis Holdings Inc. Reports Third Quarter 2023 Financial Results

09 Nov 2023 15:05:00 By Nasdaq GlobeNewswire

Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2023 Financial Results on November 9, 2023

05 Oct 2023 06:30:00 By Nasdaq GlobeNewswire

Organogenesis Applauds Withdrawal of Local Coverage Determinations by Novitas, First Coast Service Options and CGS

28 Sep 2023 08:15:00 By Nasdaq GlobeNewswire

Organogenesis Holdings Inc. to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

06 Sep 2023 15:05:00 By Nasdaq GlobeNewswire

Organogenesis Holdings Inc. Reports Second Quarter 2023 Financial Results; Withdraws Fiscal Year 2023 Guidance

09 Aug 2023 15:05:01 By Nasdaq GlobeNewswire

Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2023 Financial Results on August 9, 2023

10 Jul 2023 06:30:00 By Nasdaq GlobeNewswire

Organogenesis Holdings Inc. Reports First Quarter 2023 Financial Results

10 May 2023 15:05:01 By Nasdaq GlobeNewswire

Organogenesis President and Chief Executive Officer Gary S. Gillheeney, Sr. Elected Chair of the Board of Directors

27 Apr 2023 06:30:00 By Nasdaq GlobeNewswire

Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2023 Financial Results on May 10, 2023

10 Apr 2023 06:30:00 By Nasdaq GlobeNewswire

Organogenesis Applauds Findings from the Office of Inspector General

27 Mar 2023 07:00:01 By Nasdaq GlobeNewswire

Organogenesis Holdings Inc. Reports Fourth Quarter 2022 and Fiscal Year 2022 Financial Results; Introduces Fiscal Year 2023 Guidance

01 Mar 2023 15:02:01 By Nasdaq GlobeNewswire

Organogenesis Reports Positive Interim Analysis of Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis

01 Mar 2023 15:01:00 By Nasdaq GlobeNewswire

Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2022 Financial Results on March 1, 2023

09 Feb 2023 06:30:00 By Nasdaq GlobeNewswire

Organogenesis Holdings Inc. to Participate in the Cantor Fitzgerald Medical and Aesthetic Dermatology, Ophthalmology and Medtech Conference

05 Dec 2022 06:30:00 By Nasdaq GlobeNewswire